PAL, when combined with olaparib, inhibited Wnt/β-catenin signaling—specifically by reducing β-catenin Ser675 phosphorylation and MYC expression—thereby reversing EMT and overcoming olaparib resistance in triple-negative breast cancer [52]. This evidence concerns the gene MYC and triple-negative breast carcinoma.